Clasp Therapeutics Unveils First-in-Class KRas T Cell Engager CLSP-5282 at AACR 2026

GO BACK TO PRESS RELEASES & MEDIA Press Release April 20, 2026 Clasp Therapeutics Unveils First-in-Class KRas T Cell Engager CLSP-5282 at AACR 2026 CLSP-5282 is a first-in-class KRas-directed T cell engager (TCE) and the lead program in Clasp’s broader KRas TCE portfolio spanning multiple mutation-HLA combinations Preclinical data demonstrate potent mutation-specific tumor killing, exceptional selectivity, and robust anti-tumor activity in vitro and in vivo Tumor models with acquired resistance to a KRas inhibitor show increased sensitivity to CLSP-5282, supporting clinical evaluation both aft